Compugen (CGEN) director Eran Perry details shares, RSUs and options

Rhea-AI Filing Summary

Compugen Ltd. director Eran Perry has filed an initial Form 3 reporting his equity holdings in the company. He directly owns 10,000 Ordinary Shares and 9,216 restricted stock units, which vest in scheduled quarterly installments starting on April 1, 2026 and October 1, 2026, subject to continued service. He also holds multiple share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expiration dates between July 1, 2029 and August 5, 2035, with portions already vested and the remainder vesting in equal quarterly installments.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Perry Eran

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

3a. Foreign Trading Symbol
[CGEN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	10,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	07/01/2029	Ordinary Shares	35,000	$3.84	D
Share Option (right to buy)	(2)	07/29/2030	Ordinary Shares	10,000	$14.4	D
Share Option (right to buy)	(2)	07/27/2031	Ordinary Shares	10,000	$6.45	D
Share Option (right to buy)	(3)	03/24/2032	Ordinary Shares	10,000	$3.24	D
Share Option (right to buy)	(4)	08/03/2033	Ordinary Shares	10,000	$1.15	D
Share Option (right to buy)	(5)	07/31/2034	Ordinary Shares	8,000	$1.69	D
Share Option (right to buy)	(5)	09/12/2034	Ordinary Shares	12,000	$1.97	D
Share Option (right to buy)	(6)	08/05/2035	Ordinary Shares	10,000	$1.46	D

Explanation of Responses:

1. Includes 9,216 restricted stock units ("RSUs"). 1,716 RSUs vest in 11 equal quarterly installments commencing on April 1, 2026; and 7,500 RSUs vest 25% on October 1, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

2. Fully vested.

3. This option vested 25% on April 1, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

4. This option vested 25% on October 1, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

5. This option vested 25% on October 1, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

6. This option vests 25% on October 1, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Eran Perry	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Compugen (CGEN) director Eran Perry report in this Form 3?

Eran Perry reports his initial equity holdings in Compugen, including 10,000 Ordinary Shares, 9,216 restricted stock units, and several option grants over Ordinary Shares. The filing outlines vesting schedules and option expiration dates, establishing his baseline ownership as a company director.

How many Compugen (CGEN) Ordinary Shares does Eran Perry hold directly?

Eran Perry holds 10,000 Ordinary Shares of Compugen directly. This position is separate from his restricted stock units and share options, which provide additional potential equity exposure subject to vesting conditions and future option exercises as described in the filing.

What restricted stock units (RSUs) are disclosed for Eran Perry at Compugen (CGEN)?

The filing states Perry holds 9,216 restricted stock units. Of these, 1,716 RSUs vest in 11 equal quarterly installments from April 1, 2026, and 7,500 RSUs vest 25% on October 1, 2026, with the balance vesting in 12 quarterly installments, subject to continued service.

What option grants over Compugen (CGEN) shares does Eran Perry report?

Perry reports several share options over Ordinary Shares with exercise prices from $1.15 to $14.40 and expiration dates between July 1, 2029 and August 5, 2035. These options vest partly upfront and then in 12 equal quarterly installments, contingent on continued service.

Does this Compugen (CGEN) Form 3 show any recent insider buying or selling?

The Form 3 lists holdings rather than new transactions, so it does not show recent buying or selling activity. It simply records Perry’s existing Ordinary Shares, RSUs, and option positions as his initial statement of beneficial ownership as a director.

How do Eran Perry’s Compugen (CGEN) RSUs vest over time?

1,716 RSUs vest in 11 equal quarterly installments starting April 1, 2026. Another 7,500 RSUs vest 25% on October 1, 2026, with the remaining 75% vesting in 12 equal quarterly installments, all subject to his continued service with Compugen.